{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:37:29Z","timestamp":1793504249568,"version":"4.5.0"},"reference-count":75,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As a key member of the innate and adaptive immune response, neutrophils provide insights into the hematopoietic and inflammatory manifestations of inborn errors of immunity (IEI) and the consequences of immunotherapy. The facile recognition of IEI presenting with neutropenia provides an avenue for hematologists to facilitate early diagnosis and expedite biologically rationale care. Moreover, enhancing the understanding of the molecular mechanisms driving neutropenia in IEI\u2014decreased bone marrow reserves, diminished egress from the bone marrow, and decreased survival\u2014offers an opportunity to further dissect the pathophysiology driving neutropenia secondary to iatrogenic immune dysregulation, eg, immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.<\/jats:p>","DOI":"10.1182\/hematology.2021000285","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:17:02Z","timestamp":1639138622000},"page":"504-513","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation"],"prefix":"10.1182","volume":"2021","author":[{"given":"Kelly","family":"Walkovich","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"issue":"18","key":"2021121012081579900_hem2021000285C1","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2016-01-688887","article-title":"Neutrophil heterogeneity: implications for homeostasis and pathogenesis","volume":"127","author":"Silvestre-Roig","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2021121012081579900_hem2021000285C2","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1097\/MPH.0000000000001744","article-title":"Neutropenia is an underrecognized finding in pediatric primary immunodeficiency diseases: an analysis of the United States immunodeficiency network registry","volume":"42","author":"Michniacki","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"15","key":"2021121012081579900_hem2021000285C3","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2014-06-583260","article-title":"Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment","volume":"124","author":"Seidel","year":"2014","journal-title":"Blood"},{"key":"2021121012081579900_hem2021000285C4","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.3389\/fimmu.2018.02544","article-title":"Genes at the crossroad of primary immunodeficiencies and cancer","volume":"9","author":"Derpoorter","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"2021121012081579900_hem2021000285C5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10875-019-00656-x","article-title":"Diagnostic yield of next generation sequencing in genetically undiagnosed patients with primary immunodeficiencies: a systematic review","volume":"39","author":"Yska","year":"2019","journal-title":"J Clin Immunol"},{"issue":"3","key":"2021121012081579900_hem2021000285C6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s10875-018-0489-8","article-title":"Use of genetic testing for primary immunodeficiency patients","volume":"38","author":"Heimall","year":"2018","journal-title":"J Clin Immunol"},{"issue":"5","key":"2021121012081579900_hem2021000285C7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2021121012081579900_hem2021000285C8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaci.2018.09.018","article-title":"Neutropenia as a sign of immunodeficiency","volume":"143","author":"Sullivan","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"19","key":"2021121012081579900_hem2021000285C9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJM196811072791901","article-title":"Defective granulocyte regulation in the Chediak-Higashi syndrome","volume":"279","author":"Blume","year":"1968","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121012081579900_hem2021000285C10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J Clin Immunol"},{"issue":"7","key":"2021121012081579900_hem2021000285C11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10875-017-0434-2","article-title":"Neutropenia in patients with common variable immunodeficiency: a rare event associated with severe outcome","volume":"37","author":"Guffroy","year":"2017","journal-title":"J Clin Immunol"},{"issue":"11","key":"2021121012081579900_hem2021000285C12","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1080\/1744666X.2020.1677154","article-title":"The evaluation of neutropenia in common variable immune deficiency patients","volume":"15","author":"Ghorbani","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2021121012081579900_hem2021000285C13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2021121012081579900_hem2021000285C14","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","article-title":"Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment","volume":"38","author":"Meyts","year":"2018","journal-title":"J Clin Immunol"},{"issue":"2","key":"2021121012081579900_hem2021000285C15","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10875-018-0480-4","article-title":"Hematologic manifestations of deficiency of adenosine deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-associated bone marrow failure","volume":"38","author":"Michniacki","year":"2018","journal-title":"J Clin Immunol"},{"issue":"2","key":"2021121012081579900_hem2021000285C16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/art.41500","article-title":"Deficiency of adenosine deaminase 2 in adults and children: experience from India","volume":"73","author":"Sharma","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2021121012081579900_hem2021000285C17","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","article-title":"Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)","volume":"145","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2021121012081579900_hem2021000285C18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s10875-016-0291-4","article-title":"Hyper IgM syndrome: a report from the USIDNET registry","volume":"36","author":"Leven","year":"2016","journal-title":"J Clin Immunol"},{"issue":"5","key":"2021121012081579900_hem2021000285C19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08830180902995645","article-title":"Neutropenia and primary immunodeficiency diseases","volume":"28","author":"Rezaei","year":"2009","journal-title":"Int Rev Immunol"},{"issue":"2","key":"2021121012081579900_hem2021000285C20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1182\/blood-2004-08-2989","article-title":"Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis","volume":"106","author":"Rodrigues","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2021121012081579900_hem2021000285C21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2021121012081579900_hem2021000285C22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2012-08-447367","article-title":"High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia","volume":"121","author":"Pasquet","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2021121012081579900_hem2021000285C23","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s10875-019-00665-w","article-title":"WHIM syndrome: from pathogenesis towards personalized medicine and cure","volume":"39","author":"Heusinkveld","year":"2019","journal-title":"J Clin Immunol"},{"issue":"23","key":"2021121012081579900_hem2021000285C24","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2017-02-708552","article-title":"How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome","volume":"130","author":"Badolato","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2021121012081579900_hem2021000285C25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MPH.0b013e3181758947","article-title":"XLA-associated neutropenia treatment: a case report and review of the literature","volume":"30","author":"Jacobs","year":"2008","journal-title":"J Pediatr Hematol Oncol"},{"issue":"21 October","key":"2021121012081579900_hem2021000285C26","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","article-title":"Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"11","author":"Omar","year":"2020","journal-title":"Front Immunol"},{"issue":"November","key":"2021121012081579900_hem2021000285C27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"2021121012081579900_hem2021000285C28","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"April","key":"2021121012081579900_hem2021000285C29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","journal-title":"Eur J Cancer"},{"issue":"November","key":"2021121012081579900_hem2021000285C30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"2021121012081579900_hem2021000285C31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/CJI.0000000000000293","article-title":"Immune- related neutropenia following treatment with immune checkpoint inhibitors","volume":"43","author":"Finkel","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"2021121012081579900_hem2021000285C32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"2021121012081579900_hem2021000285C33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"issue":"4","key":"2021121012081579900_hem2021000285C34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JOP.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary","volume":"14","author":"Brahmer","year":"2018","journal-title":"J Oncol Pract"},{"issue":"suppl 1","key":"2021121012081579900_hem2021000285C35","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"2021121012081579900_hem2021000285C36","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Cancer"},{"issue":"5","key":"2021121012081579900_hem2021000285C37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/ijc.33356","article-title":"Filgrastim associations with CAR T-cell therapy","volume":"148","author":"Gaut","year":"2021","journal-title":"Int J Cancer"},{"issue":"7","key":"2021121012081579900_hem2021000285C38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2021121012081579900_hem2021000285C39","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"Hemasphere"},{"key":"2021121012081579900_hem2021000285C40","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377 (26)","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"2021121012081579900_hem2021000285C41","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"2021121012081579900_hem2021000285C42","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121012081579900_hem2021000285C43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121012081579900_hem2021000285C44","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2021121012081579900_hem2021000285C45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"2021121012081579900_hem2021000285C46","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2021121012081579900_hem2021000285C47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2021121012081579900_hem2021000285C48","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab- based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2021121012081579900_hem2021000285C49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"8","key":"2021121012081579900_hem2021000285C50","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"2021121012081579900_hem2021000285C51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jlb.64.1.72","article-title":"Giant granules of neutrophils in Chediak-Higashi syndrome are derived from azurophil granules but not from specific and gelatinase granules","volume":"64","author":"Kjeldsen","year":"1998","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2021121012081579900_hem2021000285C52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1301296","article-title":"A congenital neutrophil defect syndrome associated with mutations in VPS45","volume":"369","author":"Vilboux","year":"2013","journal-title":"N Engl J Med"},{"issue":"15","key":"2021121012081579900_hem2021000285C53","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2010-01-265942","article-title":"Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis","volume":"116","author":"McDermott","year":"2010","journal-title":"Blood"},{"issue":"17","key":"2021121012081579900_hem2021000285C54","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2016-03-706028","article-title":"Cytoskeletal abnormalities and neutrophil dysfunction in WDR1 deficiency","volume":"128","author":"Kuhns","year":"2016","journal-title":"Blood"},{"issue":"May","key":"2021121012081579900_hem2021000285C55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-6-26","article-title":"Congenital neutropenia: diagnosis, molecular bases and patient management","volume":"6","author":"Donadieu","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2021121012081579900_hem2021000285C56","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/ng.3069","article-title":"JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia","volume":"46","author":"Boztug","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"2021121012081579900_hem2021000285C57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/mgme.1999.2927","article-title":"Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome","volume":"68","author":"Introne","year":"1999","journal-title":"Mol Genet Metab"},{"issue":"August","key":"2021121012081579900_hem2021000285C58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13023-014-0132-6","article-title":"Towards the targeted management of Chediak-Higashi syndrome","volume":"9","author":"Lozano","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2021121012081579900_hem2021000285C59","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaci.2018.06.012","article-title":"Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses","volume":"143","author":"Romberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2021121012081579900_hem2021000285C60","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1007\/s10067-021-05711-w","article-title":"Expanding spectrum of DADA2: a review of phenotypes, genetics, pathogenesis and treatment","volume":"40","author":"Pinto","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"24","key":"2021121012081579900_hem2021000285C61","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2017-07-798660","article-title":"Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2","volume":"130","author":"Hashem","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2021121012081579900_hem2021000285C62","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jaci.2018.02.026","article-title":"CD40 ligand deficiency causes functional defects of peripheral neutrophils that are improved by exogenous IFN-\u03b3","volume":"142","author":"Cabral-Marques","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"2021121012081579900_hem2021000285C63","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood.V95.12.3758","article-title":"CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells","volume":"95","author":"Solanilla","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2021121012081579900_hem2021000285C64","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00005792-199611000-00001","article-title":"X-linked agammaglobulinemia. A clinical and molecular analysis","volume":"75","author":"Ochs","year":"1996","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2021121012081579900_hem2021000285C65","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/clin.1996.0188","article-title":"Neutropenia in X-linked agammaglobulinemia","volume":"81","author":"Farrar","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"issue":"4","key":"2021121012081579900_hem2021000285C66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.md.0000229482.27398.ad","article-title":"X-linked agammaglobulinemia: report on a United States registry of 201 patients","volume":"85","author":"Winkelstein","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"2021121012081579900_hem2021000285C67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/16078454.2019.1642548","article-title":"Pathogenesis of aplastic anemia","volume":"24","author":"Wang","year":"2019","journal-title":"Hematology"},{"issue":"29","key":"2021121012081579900_hem2021000285C68","doi-asserted-by":"crossref","first-page":"e4283","DOI":"10.1097\/MD.0000000000004283","article-title":"Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: a case report","volume":"95","author":"Inadomi","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"18 October","key":"2021121012081579900_hem2021000285C69","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fped.2018.00282","article-title":"Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2","volume":"6","author":"Lee","year":"2018","journal-title":"Front Pediatr"},{"issue":"5","key":"2021121012081579900_hem2021000285C70","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10875-018-0523-x","article-title":"The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions","volume":"38","author":"Rieux-Laucat","year":"2018","journal-title":"J Clin Immunol"},{"issue":"1","key":"2021121012081579900_hem2021000285C71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40425-018-0384-0","article-title":"Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab","volume":"6","author":"Hantel","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"17","key":"2021121012081579900_hem2021000285C72","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"2021121012081579900_hem2021000285C73","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete FOXP3","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2021121012081579900_hem2021000285C74","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"issue":"1","key":"2021121012081579900_hem2021000285C75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/504\/1851486\/504walkovich.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2021\/1\/504\/1851486\/504walkovich.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T12:17:58Z","timestamp":1639138678000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2021\/1\/504\/482980\/Understanding-neutropenia-secondary-to-intrinsic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,10]]},"published-print":{"date-parts":[[2021,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2021000285","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,10]]},"published":{"date-parts":[[2021,12,10]]}}}